Suppr超能文献

澳大利亚寿险公司如何使用基因检测结果?

How are genetic test results being used by Australian life insurers?

机构信息

Sydney Medical School - Northern, University of Sydney Level 7 Kolling Institute, Royal North Shore Hospital, St Leonards, NSW, 2065, Australia.

Consultant Actuary, 406/116 Belmont Rd, Mosman, NSW, 2088, Australia.

出版信息

Eur J Hum Genet. 2018 Sep;26(9):1248-1256. doi: 10.1038/s41431-018-0198-z. Epub 2018 Jun 11.

Abstract

In Australia, the USA and many Asian countries the life insurance industry is self-regulated. Individuals must disclose genetic test results known to them in applications for new or updated policies including cover for critical care, income protection and death. There is limited information regarding how underwriting decisions are made for policies with such disclosures. The Australian Financial Services Council (FSC) provided de-identified data collected on applications with genetic test result disclosure from its life insurance member companies 2010-2013 to enable repetition of an independent examination undertaken of applications 1999-2003: age; gender; genetic condition; testing result; decision-maker; and insurance cover. Data was classified as to test result alone or additional other factors relevant to risk and decision. Where necessary, the FSC facilitated clarification by insurers. 345/548 applications related to adult-onset conditions. The genetic test result solely influenced the decision in 165/345 applications: positive (n = 23), negative (n = 139) and pending (n = 3). Detailed analyses of the decisions in each of these result categories are presented with specific details of 11 test cases. Policies with standard decisions were provided for all negative test results with evidence of reassessment of previous non-standard decisions and 20/23 positive results with recognition of risk reduction strategies. Disclosure of positive results for breast/ovarian cancer, Lynch syndrome and hereditary spastic paraplegia, and three pending results, generated non-standard decisions. The examination demonstrates some progress in addressing concerns in regard to utilisation of genetic test information but the self-regulatory system in Australia only goes some way in meeting internationally recommended best practice.

摘要

在澳大利亚、美国和许多亚洲国家,寿险行业是自我监管的。个人在申请新的或更新的政策时,必须披露他们所知道的基因测试结果,包括重症监护、收入保护和死亡保险。关于有此类披露的政策的承保决策是如何做出的,信息有限。澳大利亚金融服务委员会 (FSC) 提供了其寿险成员公司在 2010 年至 2013 年期间从应用程序中收集的匿名遗传测试结果披露数据,以能够重复对 1999 年至 2003 年期间申请的独立检查:年龄;性别;遗传状况;测试结果;决策者;和保险范围。数据根据测试结果或与风险和决策相关的其他因素进行分类。如有必要,FSC 协助保险公司澄清。345/548 份与成人发病相关的申请。基因测试结果仅在 165/345 份申请中影响决策:阳性 (n=23)、阴性 (n=139) 和待定 (n=3)。对这些结果类别中的每一个决策都进行了详细分析,并提供了 11 个案例的具体细节。对于所有阴性测试结果,都提供了标准决策的政策,并证明对以前非标准决策进行了重新评估,对于 20/23 个阳性结果,承认了风险降低策略。对于乳腺癌/卵巢癌、林奇综合征和遗传性痉挛性截瘫以及三个待定结果的阳性结果,做出了非标准决策。该检查表明在利用基因测试信息方面取得了一些进展,但澳大利亚的自我监管系统仅在一定程度上符合国际推荐的最佳实践。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c74/6117272/6c2aba84e5cc/41431_2018_198_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验